Suresh 2015.

Methods	Randomised, single‐centre, open‐label trial conducted in Bengaluru, India. 2 treatment arms: CBZ and LEV
Participants	Participants aged 18‐60 years diagnosed newly with focal or partial seizures with or without secondary generalisation referred to the Department of Neurology at Vydehi Institute of Medical Sciences and Research Center Number randomised CBZ = 30, LEV = 30 30 male participants (50%) 100% participants with partial epilepsy Mean age (range): not provided for all randomised participants
Interventions	Monotherapy with CBZ or LEV Starting dose of CBZ = 200 mg/d, LEV = 500 mg/d titrated to a maximum dose of CBZ 1200 mg/d, LEV 300 mg/d Trial duration: 1 year, range of follow‐up: not stated
Outcomes	Quality of Life by the QOLIE‐10 questionnaire before and after 26 weeks of therapy Treatment efficacy (seizure freedom at 4 weeks, 12 weeks, 26 weeks and 6 months) Treatment safety (proportion of participants experiencing at least 1 adverse event)
Notes	Outcomes chosen for this review were not reported; contact could not be made with trial author to provide IPD
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Trial described as randomised, no further information provided
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label trial
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open‐label trial
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition rates reported, two participants lost to follow‐up in each group not included in analysis. This is not an ITT approach but unlikely that this small amount of missing data would influence the overall results
Selective reporting (reporting bias)	High risk	Only one outcome is predefined in the methods section (Quality of Life), other results reported were not predefined
Other bias	Low risk	None identified